INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 438m ago
HOUSE PTR38m ago
SEC 13F38m ago
ROBINHOOD CHAIN38m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Vultaggio Vincent sold ZNTL

PAO and PFO · Zentalis Pharmaceuticals, Inc. · Common Stock

Side
SELL
Value
$1,398
Shares
556
Price
$2.52
Executed
Feb 3, 2026
Disclosed
Feb 4, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Feb 3 executedFeb 4, 2026 disclosed

ZNTL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
1/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+1 / 25

    $1K reported value · 0.3% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ZNTL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    17
    KE
    Kariuki EnochDirector
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    57.1K sh
    		Jun 16, 2026Jun 18, 2026
    traded Jun 16, 2026
    		+2dSEC FORM 4

    Evidence

    17
    JM
    Johnson David MichaelDirector
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    57.1K sh
    		Jun 16, 2026Jun 18, 2026
    traded Jun 16, 2026
    		+2dSEC FORM 4

    Evidence

    17
    SJ
    Skvarka JanDirector
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    57.1K sh
    		Jun 16, 2026Jun 18, 2026
    traded Jun 16, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CS
    Campbell ShannonDirector
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    114.2K sh
    		May 26, 2026May 27, 2026
    traded May 26, 2026
    		+1dSEC FORM 4

    Evidence

    8
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$73K
    30.0K sh
    		Feb 6, 2026Feb 10, 2026
    traded Feb 6, 2026
    		+4dSEC FORM 4

    Evidence

    1
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$8,086
    3,379 sh
    		Feb 9, 2026Feb 10, 2026
    traded Feb 9, 2026
    		+1dSEC FORM 4

    Evidence

    1
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$17K
    6,894 sh
    		Feb 10, 2026Feb 10, 2026
    traded Feb 10, 2026
    		+0dSEC FORM 4

    Evidence

    5
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$6,477
    2,540 sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    Bruns IngmarChief Medical Officer
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    365.0K sh
    		Jan 8, 2026Jan 9, 2026
    traded Jan 8, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BB
    Bucher James BChief Legal Officer
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    100.0K sh
    		Jan 8, 2026Jan 9, 2026
    traded Jan 8, 2026
    		+1dSEC FORM 4

    Evidence

    9
    VV
    Vultaggio VincentPAO and PFO
    ZNTLZentalis Pharmaceuticals, Inc.
    Grant or award
    		A—
    100.0K sh
    		Jan 8, 2026Jan 9, 2026
    traded Jan 8, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002018766-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 3, 2026
    Published
    Feb 4, 2026
    Ingested by INSIDER
    Nov 5, 04:19 UTC
    Last re-read
    Nov 5, 04:19 UTC

    Extracted facts

    Filer
    Vultaggio Vincent
    Role
    PAO and PFO
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Zentalis Pharmaceuticals, Inc.
    Ticker
    ZNTL
    Shares
    556
    Price per share
    $2.52
    Value
    $1,398
    Execution date (reported)
    Feb 3, 2026
    Owned after transaction
    186.7K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 556
    • Price: $2.515

    = $1,398

    What this establishes

    Vultaggio Vincent filed this Form 4 reporting a open-market sale of ZNTL on Feb 3, 2026. It became public on Feb 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    PAO and PFO
    Vultaggio Vincentcik:0002018766
    Issuer
    Zentalis Pharmaceuticals, Inc.cik:0001725160

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.